Moderna, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Moderna, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $10.00M, a 16.67% decline year-over-year.
- Moderna, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $6.00M, a 25.00% decline year-over-year.
- Moderna, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Moderna, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $12.00M, a 20.00% increase year-over-year.
- Moderna, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $18.00M, a 25.00% decline from fiscal 2024.
- Moderna, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $24.00M, a 14.29% increase from fiscal 2023.
- Moderna, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $21.00M, a 40.00% increase from fiscal 2022.
- Moderna, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $15.00M, a 25.00% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $10.00M 10-Q · filed 2026-07-31 | |
| 2025-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $18.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2025-06-30 | $12.00M 10-Q · filed 2026-07-31 | |
| 2024-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $24.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $6.00M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $10.00M 10-Q · filed 2025-08-01 | |
| 2023-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $21.00M 10-K · filed 2026-02-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $12.00M 10-Q · filed 2024-08-01 | |
| 2022-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $15.00M 10-K · filed 2025-02-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | |
| 2022-06-30 | $9.00M 10-Q · filed 2023-08-03 | |
| 2021-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $12.00M 10-K · filed 2024-02-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | |
| 2021-06-30 | $5.00M 10-Q · filed 2022-08-03 | |
| 2020-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $7.00M 10-K · filed 2023-02-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | |
| 2020-06-30 | $3.00M 10-Q · filed 2021-08-05 | |
| 2019-12-31 | $3.00M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |